Volume : 11, Issue : 02, February – 2024
Title:
A REVIEW ARTICLE ON FLECAINIDE
Authors :
R. Jona Methusala, B. Gowthami
Abstract :
Flecainide acetate is a class IC antiarrthythamic agent and its clinical efficacy has been confirmed by the its results of several cilinical trails. Now days , flecainide is recommmened as one the first line therapies for pharmacological conversion as welll as maintenance of sinus rhythm in patient with aterial fibrillation and /or supraventricular tachycardias. Based on the caedic arrythmia suppression trail study results , flecainide is not recommened in patient with structural heart disease due to hiogt proarrthymic risk. Recent data support the role of flecainide in preventing ventricular tachyarrthyminergic polymorphic ventricular tachycardia associated both with ryanodinre receptor and calsequestrin mutation. we herein review the current clinical data related to flecainide use in clinical practice and some concerns about its role in the management of patients with coronay artery disease.
Keywords: Atrial fibrillation: class IC anti-arrhythmic drugs: Flecinaide proarrthythmia: ventricular tachycardia.
Cite This Article:
Please cite this article in press R. Jona Methusala et al., A Review Article On Flecainide, Indo Am. J. P. Sci, 2024; 11 (02).
Number of Downloads : 10
References:
1. “Flecainide Acetate Monograph for Professionals” . Drugs.com. American Society of Health-System Pharmacists . Retrieved 7 April 2019.
2. ^ Jump up to:a b c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 103. ISBN 9780857113382.
3. ^ “Flecainide (Tambocor) Use During Pregnancy” . Drugs.com . Retrieved
4. Hindricks, G.; Potpara, T.; Dagres, N.; Arbelo, E.;Bax, J.J.; Blomström- Lundqvist, C.; Boriani, G.; Castella, M.; Dan, G.-A.; Dilaveris, P.E.; et al. 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association of Cardio-Thoracic Surge ry (EACTS). Eur. Heart J. 2020, ehaa612.Rocca, D.G.; Mohanty, S.; Trivedi, C.; Biase, L.D.; Natale, A. Percutaneous Treatment of Non -Paroxysmal Atrial Fibrillation: A Paradigm Shift from Pulmonary Vein to Non-Pulmonary Vein Trigger Ablation?Arrhythm. Electrophysiol. Rev. 2018, 7, 256.
5. Nieuwlaat, R.; Capucci, A.; Camm, A.J.; Olsson, S.B.; Andresen, D.; Davies, D.W.; Cobbe, S.; Breithardt, G.; Le Heuzey, J.-Y.; Prins, M.H.; et al. Atrial Fibrillation Management: A Prospective Survey in ESC Member Countries. Eur. Heart J. 2005, 26, 2422 –2434.
6. Saksena, S.; Slee, A.; Waldo, A.L.; Freemantle, N.; Reynolds, M.; Rosenberg, Y.; Rathod, S.; Grant, S.; Thomas, E.; Wyse, D.G. Cardiovascular Outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). J. Am. Coll. Cardiol. 2011, 58, 1975 –1985.
7. Allen LaPointe, N.M.; Dai, D.; Thomas, L.; Piccini, J.P.; Peterson, E.D.; Al – Khatib, S.M. Comparisons of Hospitalization Rates Among Younger Atrial Fibrillation Patients Receiving Different Antiarrhythmic Drugs. Circ. Cardiovasc. QualOutcomes 2015, 8,292 –300.
8. Echt, D.S.; Liebson, P.R.; Mitchell, L.B.; Peters, R.W.; Obias-Manno, D.; Barker, A.H.; Arensberg, D.; Baker, A.; Friedman, L.; Greene, H.L.; et al. Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo: The Cardiac Arrhythmia Sup pression Trial. N. Engl. J. Med. 1991, 324, 781 –788.
9. Conard, G.J.; Ober, R.E. Metabolism of Flecainide.Am. J. Cardiol. 1984, 53, B41 B51.
10. Anderson, J.L.; Stewart, J.R.; Perry, B.A.; Van Hamersveld, D.D.; Johnson, T.A.; Conard, G.J.; Chang, S.F.; Kvam, D.C.; Pitt, B. Oral Flecainide Acetate for the Treatment of Ventricular Arrhythmias’. Engl. J. Med. 1981, 305, 473 –477.
11. Tjandra -Maga, T.; Verbesselt, R.; Hecken, A.; Mullie, A.; Schepper, P. Flecainide: Single and Multiple Oral Dose Kinetics, Absolute Bioavailability and Effect of Food and Antacid in Man.Br. J. Clin. Pharmacol. 1986, 22, 309 –316.
12. Holmes, B.; Heel, R.C. Flecainide A Preliminary Review of Its Pharmacodynamic Properties and Therapeutic Efficacy.Drugs 1985, 29, 1 –33.
13. Josephson, M.A.; Ikeda, N.; Singh, B.N. Effects of Flecainide on Ventricular Function: Clinical and Experimental Correlations. Am. J. Cardiol. 1984, 53, B95 – B100.
14. Campbell, T.J.; Williams, E.M.V. Voltage- and Time -Dependent Depression of Maximum Rate of Depolarisation of Guinea -Pig Ventricular Action Potentials by Two New Antiarrhythmic Drugs, Flecainide and Lorcainide.Cardiovasc.Res. 1983, 17, 251 –25
15. Moss AJ, Schwartz PJ, Crampton RS,et al The long QT syndrome. Prospective longitudinal study of 328 familiesC. irculation 1991;84: 1136–1144.
16. Splawski I, Shen J, Timothy KW,et al Spectrum of mutations in long‐QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000;102: 1178–1185.
17. Plaster NM, Tawil R, Tristani‐Firouzi M, et al Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen’s syndrome .Cell 2001;105: 511–519.
18. Mohler PJ, Schott JJ,Gramolini AO, et al Ankyrin ‐B mutation causes type 4 long‐ QT cardiac arrhythmia and sudden cardiac deathN. ature 2003;421: 634–639.
19. Dumaine R, Wang Q, Keating MT,et al Multiple mechanisms of Na+ channel‐ linked long ‐QT syndrome .Circ Res 1996;78: 916–924.
20. Schwartz PJ, Priori SG, Locati EH, et al Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene‐specific therapy (see comments) C. irculation 1995;92: 3381–3386.
21. Rosero S, Zareba W, Robinson JL,et al Gene ‐specific therapy for long QT syndrome: QT shortening with lidocaine and tocainide in patients with mutation of the sodium channel gene.Ann Noninvasive Electrocardiol1997;2: 274–278.
22. Benhorin J, Taub R, Goldmit M,et al Effects of flecainide in patients with new SCN5A mutation: Mutation‐specific therapy for long‐QT syndrome? Circulation 2000;101: 1698–1706.
23. Windle JR, Geletka RC, Moss AJ, et al Normalization of ventricular repolarization with flecainide in long qt syndrome patients with scn5a:deltakpq mutation Noninvasive Electrocardiol 2001;6: 153–158.
24. Nagatomo T, January CT, Makielski JC.Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide Pharmacol 2000;57: 101–107.
25. Echt DS, Liebson PR, Mitchell LBet al Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial . N Engl J Med 1991;324: 781–788.
26. Antzelevitch C.The Brugada syndrome: Ionic basis and arrhythmia mechanisms .J Cardiovasc Electrophysiol2001;12: 268–272. Chen Q, Kirsch GE, Zhang D,et al Genetic basis and molecularmechanism for idiopathic ventricular fibrillationN. ature 1998;392: 293–296.
27. Bezzina C, Veldkamp MW, Van Den Berg MP,et al A single Na(+) channel mutation causing both long‐QT and Brugada syndromes 1213. C.irc Res 1999;85: 1206–
28. Veldkamp MW, Viswanathan PC, Bezzina C,et al Two distinct congenital arrhythmias evoked by a Mult dysfunctional Na(+) channel E97. Ci.rc Res 2000;86: E91.
29. Priori SG, Napolitano C, Schwartz PJ,et al The elusive link between LQT3 and Brugada syndrome: The role of flecainide challenge Ci.rculation 2000;102: 945–947.
30. Bennett PB. Long QT syndrome: Biophysical and pharmacologic mechanisms in LQT3. J Cardiovasc Electrophysiol2000;11: 819–822.
31. Abriel H, Wehrens XH, Benhorin J,et al Molecular pharmacology of the sodium channel mutation D1790G linked to the long‐QT syndrome921– C. irculation 2000;102: 925.
32. Wehrens XH, Abriel H, Cabo C,et al Arrhythmogenic mechanism of an LQT‐3 mutation of the human heart Na(+) channel alpha‐subunit: A computational analysis .Circulation 2000;102: 584–590.